Healthcare / Medical Instruments & SuppliesNasdaqGS
$3.06
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $23.6M · quality 39.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
2/100
F
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$220M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-20.2%
↓Gross Margin
41.9%
↓Debt/Equity
N/A
•Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2009–2025 · 16 años de histórico normalizado
Revenue CAGR
+2.5%
FCF CAGR
—
FCF margin
-46.3%
FCF / Net income
0.77x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $115.0M · net income $-68.7M · FCF $-53.2M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||||||||||
| Revenue | $115.0M | $115.0M | $185.8M | $405.5M | $387.5M | $233.7M | $171.7M | $154.6M | $181.7M | $167.1M | $128.2M | $119.7M | $106.5M | $98.9M | $87.8M | $81.9M | $75.0M | $77.0M |
| Net Income | $-68.7M | $-68.7M | $-19.5M | $53.7M | $-17.1M | $-23.0M | $-14.9M | $16.7M | $20.4M | $30.9M | $19.7M | $8.2M | $-4.6M | $-11.2M | $-15.1M | $-8.8M | $-3.5M | $-7.8M |
| EBITDA | $-61.8M | $-61.8M | $-17.4M | $53.6M | $-6.8M | $1.5M | $4.2M | $25.9M | $34.9M | $46.3M | $26.0M | $13.9M | $1.5M | $-5.6M | $-9.0M | $-4.5M | $-342000.00 | $-5.7M |
| EPS | -0.94 | -0.94 | -0.26 | 0.72 | -0.24 | -0.32 | 0.22 | 0.27 | 0.33 | 0.51 | 0.35 | 0.14 | -0.08 | -0.20 | -0.29 | -0.19 | -0.08 | — |
| Gross Margin | 41.9% | 41.9% | 42.7% | 42.3% | 38.3% | 50.3% | 59.3% | 61.2% | 62.5% | 59.2% | 68.7% | 67.1% | 62.6% | 59.2% | 63.3% | 63.2% | 63.1% | 61.2% |
| Operating Margin | -62.6% | -62.6% | -15.2% | 8.1% | -5.7% | -4.3% | -3.0% | 12.0% | 15.6% | 24.1% | 15.8% | 6.7% | -4.5% | -12.3% | -18.5% | -11.5% | -4.5% | -11.4% |
| Net Margin | -59.8% | -59.8% | -10.5% | 13.2% | -4.4% | -9.8% | -8.7% | 10.8% | 11.2% | 18.5% | 15.4% | 6.8% | -4.3% | -11.3% | -17.2% | -10.8% | -4.7% | -10.1% |
| Cash Flow | ||||||||||||||||||
| Free Cash Flow | $-53.2M | $-53.2M | $23.6M | $135.8M | $-54.0M | $-57.3M | $-20.9M | $490000.00 | $32.7M | $23.8M | $20.2M | — | — | $5.9M | $-7.4M | $-5.5M | $1.8M | $-1.5M |
| Returns | ||||||||||||||||||
| ROE | -20.2% | -20.2% | -4.8% | 12.5% | -4.7% | -6.0% | -3.7% | 5.4% | 7.2% | 12.0% | 10.6% | 5.1% | -2.9% | -6.9% | -8.9% | -8.8% | -3.4% | -7.5% |
| Growth & Yield | ||||||||||||||||||
| Revenue Growth | -38.1% | -38.1% | -54.2% | 4.6% | 65.8% | 36.1% | 11.1% | -14.9% | 8.8% | 30.3% | 7.1% | 12.5% | 7.6% | 12.7% | 7.3% | 9.2% | -2.6% | — |
| EPS Growth | -261.5% | -261.5% | -136.1% | 400.0% | 25.0% | -245.5% | -18.5% | -18.2% | -35.3% | 45.7% | 150.0% | 275.0% | 60.0% | 31.0% | -52.6% | -137.5% | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Unavailable: positive start/end prices are required.